Blog

Contrasting Editas Medicine (NASDAQ:EDIT) & OpGen (OPGN) – StockNewsTimes

Contrasting Editas Medicine (NASDAQ:EDIT) & OpGen (OPGN)
StockNewsTimes
It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9

and more »

2018-03-29 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.